10 results on '"Chi, Pei-Dong"'
Search Results
2. Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer/T cell lymphoma
- Author
-
Wang, Liang, Chi, Pei-dong, Chen, Hao, Xiang, Jin, Xia, Zhong-jun, and Zhang, Yu-jing
- Published
- 2014
- Full Text
- View/download PDF
3. Rinsing sampling of core needle biopsy for flow cytometric analysis: A favorable method for lymphoma diagnosis.
- Author
-
Chi, Pei‐Dong, Liu, Yi‐Jun, Huang, Yu‐Hua, Mao, Ming‐Jie, Wang, Yu, Li, Zhi‐Ming, and Li, Jian
- Subjects
- *
CORE needle biopsy , *CANCER diagnosis , *DRILL core analysis , *CELL suspensions , *DIAGNOSIS methods - Abstract
Background: Conventional protocols utilize core needle biopsy (CNB) or fine needle aspiration (FNA) to produce cell suspension for flow cytometry (FCM) is a diagnostic challenge for lymphoid malignancies. We aim to develop an alternative CNB rinsing technique (RT) to produce cell suspension for FCM during this mini‐invasive procedure of CNB for lymphoma diagnosis. Methods: FNA and CNB specimens from the same lesion of 93 patients with suspected lymphoma were collected under the guidance of B‐ultrasound simultaneously. The fresh CNB samples were prepared to cell suspension by RT for FCM immunophenotyping analysis (Group CNB‐RT). Then, the CNB tissues after performing the RT process and the fresh FNA tissues were processed by conventional tissue cell suspension (TCS) technique to obtain the cell suspensions (Groups of CNB‐TCS & FNA‐TCS), respectively, as comparison. The diagnostic efficacies, as well as the concordances of the FCM results with reference to the morphologic diagnoses were compared in these three groups. Results: RT could yield sufficient cells for FCM immunophenotyping analysis, though a lower cell numbers compared to TCS technique. The diagnostic concordance was comparable in group CNB‐RT (91.1%) to the group CNB‐TCS (88.9%) and group FNA‐TCS (88.4%) (p = 0.819). The diagnostic sensitivity and specificity of CNB‐RT (91.1%; 100%) was not inferior to that of CNB‐TCS (88.9%; 100%) and FNA‐TCS (88.4%; 98.8%). Conclusions: This study shows the CNB‐RT presented non‐inferior diagnostic concordance and efficacy as compared to the TCS technique. CNB‐RT has the potential to produce cell suspension for FCM immunophenotyping while preserving tissue for lymphoma diagnosis and research. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. A prognostic stemness biomarker CCDC80 reveals acquired drug resistance and immune infiltration in colorectal cancer.
- Author
-
Wang, Wei‐Da, Wu, Guo‐Yan, Bai, Kun‐Hao, Shu, Ling‐Ling, Chi, Pei‐Dong, He, Si‐Yuan, Huang, Xin, Zhang, Qian‐Yi, Li, Liang, Wang, Da‐Wei, and Dai, Yu‐Jun
- Published
- 2020
- Full Text
- View/download PDF
5. A novel score based on serum apolipoprotein A-1 and C-reactive protein is a prognostic biomarker in hepatocellular carcinoma patients.
- Author
-
Mao, Minjie, Wang, Xueping, Sheng, Hui, Liu, Yijun, Zhang, Lin, Dai, Shuqin, and Chi, Pei-dong
- Subjects
LIVER cancer ,APOLIPOPROTEINS ,PROGNOSIS ,BLOOD lipoproteins ,FORECASTING - Abstract
Background: The aim of this study was to propose a prognostic scoring system based on preoperative serum apolipoprotein A-1 and C-reactive protein (ApoA-1 and CRP, AC score) levels and to evaluate the prognostic value of these markers in patients with hepatocellular carcinoma (HCC).Methods: In all, 539 consecutive cases diagnosed with HCC from 2009 to 2012 at Sun Yat-sen University Cancer Center were analysed. The characteristics and levels of pretreatment lipids (ApoA-1, apolipoprotein B (Apo-B), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglycerides (TGs)) and CRP were reviewed and determined by univariate and multivariate Cox hazard models. Then, the AC score was proposed, which combines two independent risk factors (ApoA-1 and CRP).Results: The optimal cut-off points in our study were determined according to established reference ranges. Patients with decreased ApoA-1 levels (< 1.090 g/L) and increased CRP levels (≥3.00 mg/L) exhibited a significantly poor overall survival (OS) and disease-free survival (DFS). The AC score was calculated as follows: patients with decreased ApoA-1 and elevated CRP were given a score of 3, patients with only one of these abnormalities were given a score of 2, and those with no abnormalities were given a score of 1. Patients with a higher AC score showed more progressive disease and a poorer prognosis. This was observed not only in the entire cohort (for OS, P < 0.001; for DFS, P < 0.001) but also in the subgroups stratified by pathological stage (stage I-II and stage III-IV). The discriminatory ability of the AC score in HCC was assessed according to the AUC values. The AUC value of the AC score (AUC: 0.676, 95% CI: 0.629-0.723, P < 0.001) was higher than that of AFP. In addition, the combination of the AFP and AC scores (AUC: 0.700, 95% CI: 0.655-0.745, P < 0.001) was superior to the AFP and AC scores alone.Conclusions: The AC score is a significant valuable predictor of OS and DFS and could more accurately differentiate the prognosis of HCC patients. As this study is a retrospective analysis, the value of the AC score should be validated in large prospective trials. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
6. A Simple and Effective Method for Flow Cytometric Study of Lymphoid Malignancies Using Needle Core Biopsy Specimens.
- Author
-
Chi, Pei‐Dong, Freed, Natalie S., Wake, Laura, Page, Cynthia, Smith, Lynette M., Amador, Catalina, Qureishi, Hina Naushad, Greiner, Timothy C., Rodig, Scott J., Pirruccello, Samuel J., Yuan, Ji, and Fu, Kai
- Published
- 2018
- Full Text
- View/download PDF
7. Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
- Author
-
Mao, Min-jie, Xue, Ning, Wang, Xue-ping, Chi, Pei-dong, Liu, Yi-jun, Huang, Qi, Dai, Shu-qin, and Liu, Wan-li
- Subjects
CHEMOKINES ,BIOMARKERS ,NASOPHARYNX cancer ,EPSTEIN-Barr virus ,IMMUNOGLOBULIN A ,CAPSIDS - Abstract
Background: To investigate the predictive value of chemokine CCL27 for identifying early stage nasopharyngeal carcinoma (NPC) patients within a population seropositive for Epstein-Barr virus (EBV) capsid antigen-specific IgA (VCA-IgA).Methods: CCL27 in plasma samples from 104 NPC patients, 112 VCA-IgA-positive healthy donors, and 140 VCA-IgA-negative normal subjects was measured by ELISA. Expression of CCL27 in nasopharyngeal tissue from 20 VCA-IgA-positive healthy donors and 20 NPC patients was examined by immunohistochemical staining.Results: Levels of CCL27 in the plasma of VCA-IgA-positive healthy donors (607.33 ± 218.81 pg/ml) were significantly higher than the levels in all NPC patients (437.09 ± 217.74, P = < 0.0001) and in the subset of patients with early stage NPC (463.85 ± 226.17, P = 0.0126). Plasma CCL27 levels were significantly lower in the VCA-IgA-negative normal subjects (358.22 ± 133.15 pg/ml) than in either the VCA-IgA-positive healthy donors (P < 0.0001) or the NPC patients (P = 0.0113). CCL27 protein was detected in 16 of 20 (80%) nasopharyngeal tissue samples from VCA-IgA-positive healthy donors and in 3 of 20 (15%) tumor tissue samples from NPC patients. There was no relationship between CCL27 levels and VCA-IgA titers or plasma EBV DNA content. Receiver operating characteristic (ROC) curves demonstrated that plasma CCL27 levels had a sensitivity of 67.00%, a specificity of 73.10%, and an area under the ROC of 0.725 (95% confidence interval [CI]: 0.657-0.793) for distinguishing between NPC patients and VCA-IgA-positive healthy donors. Further analysis showed that CCL27 levels could distinguish between early stage NPC patients and VCA-IgA-positive healthy donors with an area under the ROC of 0.712 (95% CI: 0.560-0.865), a sensitivity of 59.80%, and a specificity of 84.60%.Conclusions: Chemokine CCL27 could successfully identify NPC patients within a VCA-IgA-positive population. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
8. High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma.
- Author
-
Wang, Hua, Wang, Liang, Chi, Pei-dong, Wang, Wei-da, Chen, Xiao-qin, Geng, Qi-rong, Xia, Zhong-jun, and Lu, Yue
- Subjects
MULTIPLE myeloma diagnosis ,INTERLEUKINS ,MULTIPLE myeloma ,PROGNOSIS ,SURVIVAL analysis (Biometry) ,PREDICTIVE tests - Abstract
Background: Interleukin-10 (IL-10) is a inhibiting inflammatory cytokine that plays an important role in immune suppressive microenvironment in multiple myeloma (MM). Whether the level of serum IL-10 could predict treatment response and survival outcomes or not needs to be investigated in MM patients.Methods: The level of IL-10 in serum was measured using enzyme-linked immunosorbent assay in 188 patients with newly diagnosed MM.Results: The best cutoff value for IL-10 in predicting survival is 169.69 pg ml(-1) with an area under the curve (AUC) value of 0.747 (P<0.001). In all, 92 patients (48.9%) were classified as high-IL-10 group (>169.96 pg ml(-1)) and 96 patients (51.1%) as low-IL-10 group (⩽169.96 pg ml(-1)). The overall response rate (ORR) was 79.2% in low-IL-10 group, significantly higher than that in high-IL-10 group (53.3%, P<0.001). Patients in low-IL-10 group had significantly better survival compared with those in high-IL-10 group (3-year PFS rate: 69.3% vs 13.3%, P<0.001; 3-year OS rate: 93.6% vs 51.9%, P<0.001). Multivariate analysis revealed that serum IL-10 level >169.96 pg ml(-1) at diagnosis and certain cytogenetic abnormalities were two adverse factors for PFS and OS.Conclusions: Our data suggest that serum IL-10 at diagnosis is a novel, powerful predictor of prognosis for MM. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
9. High-Density Lipoprotein Cholesterol Is a Favorable Prognostic Factor and Negatively Correlated with C-Reactive Protein Level in Non-Small Cell Lung Carcinoma.
- Author
-
Chi, Pei-Dong, Liu, Wen, Chen, Hao, Zhang, Jing-Ping, Lin, Yuehao, Zheng, Xin, Liu, Wanli, and Dai, Shuqin
- Subjects
- *
LUNG cancer prognosis , *HIGH density lipoproteins , *C-reactive protein , *INFLAMMATION , *BLOOD serum analysis , *BLOOD lipids , *BIOMARKERS - Abstract
Background: Although the alterations of lipid profile in lung cancer have been documented, the prognostic value of serum HDL-C level and its correlation with inflammation in NSCLC remain unknown. Subjects and Methods: Levels of preoperative serum lipid concentrations (including HDL-C, LDL-C, TC, and TG) and the inflammatory biomarker C-reactive protein level (CRP) were retrospectively analyzed in 228 patients with NSCLC and in 300 healthy controls. The serum lipid levels in these two populations were compared. Univariate and multivariate cox hazards analyses were performed to investigate the prognostic value of serum lipid levels in NSCLC. The correlation between CRP and lipid profile were also analyzed. Results: Compared with those in normal controls, the serum HDL-C, LDL-C, and TC levels were statistically decreased and the TG levels were significantly increased in 228 NSCLC patients. The patients with decreased levels of HDL-C had significantly lower 5-year survival rates than those with normal HDL-C, not only in the whole NSCLC cohort but also in the subgroups stratified according to the disease T, N classifications, and metastasis, whereas the other lipid components were not independent prognostic factors for NSCLC. Of the lipid components, a lower HDL-C level was observed more often in patients with a high CRP level than in those with a normal CRP level. Spearman’s rank correlation analysis revealed that the HDL-C level presented a negative correlation with the CRP level (r = −0.360, p<0.001). Conclusions: A decreased level of preoperative HDL-C was found to be associated with poor survival in patients with NSCLC. Serum HDL-C level may be a clinical prognosis factor for NSCLC patients. In addition, a negative correlation was present between the levels of HDL-C and CRP, the well-known inflammation biomarker. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
10. Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma.
- Author
-
Zheng, Xin, Xing, Shan, Liu, Xiao-Min, Liu, Wen, Liu, Dan, Chi, Pei-Dong, Chen, Hao, Dai, Shu-Qin, Zhong, Qian, Zeng, Mu-Sheng, and Liu, Wan-Li
- Subjects
CELL lines ,ESOPHAGEAL tumors ,GENES ,PEPTIDE hormones ,PROTEINS ,SQUAMOUS cell carcinoma ,TUMOR antigens ,TUMOR markers ,DIAGNOSIS - Abstract
Background: Elevated serum YKL-40 levels have been observed in various cancers. We evaluated the diagnostic performance of serum YKL-40 alone or in combination with the CEA, CYFRA21-1 and SCCA tumor markers for patients with esophageal squamous cell carcinoma (ESCC).Methods: YKL-40 was detected in ESCC cell lines and tissues by real-time RT-PCR, Western blotting and ELISA. YKL-40 protein expression was determined in 20 ESCC tumor tissues using immunohistochemistry. Serum YKL-40 was measured by ELISA in 126 healthy donors, 59 patients with benign esophageal diseases and 150 patients with ESCC. Serum CEA, CYFRA21-1 and SCCA were determined by electrochemiluminescence.Results: YKL-40 mRNA and protein were observed in ESCC cancer cell lines, tissues and cell culture media, respectively. YKL-40 expression was observed in 17 of 20 ESCC samples (85%). Serum YKL-40 concentration was significantly elevated in patients with ESCC (Range: 6.95-502.10 ng/ml) compared with patients with benign diseases (Range: 1.21-429.30 ng/ml; P = 0.038) and healthy controls (Range: 2.56-132.26 ng/ml; P < 0.001). ROC curves demonstrated that serum YKL-40 has a sensitivity of 72.70%, a specificity of 84.13% and an AUC of 0.874 for the diagnosis of ESCC, which was superior to CEA (Sen: 8.00%; Spe: 96.80%, AUC = 0.652), CYFRA21-1 (Sen: 40.00%; Spe: 92.06%, AUC = 0.746) and SCCA (Sen: 32.67%; Spe: 94.44%, AUC = 0.789). The YKL-40 and SCCA combination was better for diagnosing ESCC (Sen: 82.00%, Spe: 79.37%, PPV: 82.55 and NPV: 78.74; AUC = 0.917) than the YKL-40 and CEA combination (Sen: 74.00%, Spe: 83.20%, PPV: 84.09 and NPV: 72.73; AUC = 0.877), the YKL-40 and CYFRA21-1 combination (Sen: 82.00%, Spe: 77.78%, PPV: 81.46% and NPV: 78.40%; AUC = 0.897) or the CEA, CYFRA21-1 and SCCA combination (Sen: 56.67%, Spe: 84.80%, PPV: 81.73 and NPV: 61.99; AUC = 0.831). Associations between serum YKL-40 levels and the clinic characteristics of ESCC were not significant, with the exception of age (p = 0.001).Conclusions: ESCC tumor cells and tissues express YKL-40. Serum YKL-40 may be a potential biomarker for ESCC. Serum YKL-40 in combination with SCCA significantly increases the sensitivity of detecting ESCC. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.